Wang C, Li K, Huang R, Wan S, Chen S, Liu S
BMC Cancer. 2025; 25(1):271.
PMID: 39955518
PMC: 11830209.
DOI: 10.1186/s12885-025-13668-1.
Ikarashi D, Kawamura T, Ogasawara K, Arakawa Y, Machida A, Ito A
Front Oncol. 2025; 14:1493922.
PMID: 39943993
PMC: 11813790.
DOI: 10.3389/fonc.2024.1493922.
Chao C, Hung C, Lai W, Tung C, Yeh W, Yang K
Virol J. 2025; 22(1):32.
PMID: 39923063
PMC: 11806556.
DOI: 10.1186/s12985-025-02643-8.
Wu Y, Gong Y, Zhou L, Xu A, Li X
Mol Biomed. 2025; 6(1):8.
PMID: 39920484
PMC: 11805734.
DOI: 10.1186/s43556-025-00245-y.
Lyu T, Wu K, Zhou Y, Kong T, Li L, Wang K
Cancer Sci. 2024; 116(3):710-723.
PMID: 39726326
PMC: 11875766.
DOI: 10.1111/cas.16436.
Bladder cancer biomarkers: current approaches and future directions.
Ahangar M, Mahjoubi F, Mowla S
Front Oncol. 2024; 14:1453278.
PMID: 39678505
PMC: 11638051.
DOI: 10.3389/fonc.2024.1453278.
Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma.
Flechon A, Morales-Barrera R, Powles T, Alva A, Ozguroglu M, Csoszi T
Clin Cancer Res. 2024; 30(23):5353-5364.
PMID: 39475359
PMC: 11609623.
DOI: 10.1158/1078-0432.CCR-23-3518.
m6A reader IGF2BP2 promotes M2 macrophage polarization and malignant biological behavior of bladder cancer by stabilizing NRP1 mRNA expression.
Fu D, Shi X, Yi X, Wu D, He H, Zhou W
BMC Urol. 2024; 24(1):147.
PMID: 39014364
PMC: 11251312.
DOI: 10.1186/s12894-024-01534-4.
Global burden, risk factors, and temporal trends of ureteral cancer: a comprehensive analysis of cancer registries.
Huang J, Pang W, Fung Y, Mak F, Chan S, Liu X
BMC Med. 2024; 22(1):264.
PMID: 38915094
PMC: 11197334.
DOI: 10.1186/s12916-024-03485-x.
New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma.
Meneceur S, De Vos C, Petzsch P, Kohrer K, Niegisch G, Hoffmann M
J Cell Mol Med. 2024; 28(9):e18342.
PMID: 38693852
PMC: 11063726.
DOI: 10.1111/jcmm.18342.
Establishment and validation of a nomogram for predicting overall survival of upper-tract urothelial carcinoma with bone metastasis: a population-based study.
Hu J, Gu H, Zhang D, Wen M, Yan Z, Song B
BMC Urol. 2024; 24(1):100.
PMID: 38689213
PMC: 11059636.
DOI: 10.1186/s12894-024-01488-7.
Clinical Pharmacology of the Antibody-Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors.
Tang M, Garg A, Bonate P, Rosenberg J, Matsangou M, Kadokura T
Clin Pharmacokinet. 2024; 63(4):423-438.
PMID: 38609704
PMC: 11052883.
DOI: 10.1007/s40262-024-01369-0.
Effect of a variant histology on the oncological outcomes of Japanese patients with upper tract urothelial carcinomas after radical nephroureterectomy: a multicenter retrospective study.
Uchida N, Urabe F, Suhara Y, Goto Y, Yoshihara K, Sadakane I
Transl Androl Urol. 2024; 13(3):414-422.
PMID: 38590954
PMC: 10999016.
DOI: 10.21037/tau-23-561.
Real-world epidemiology and treatment patterns of patients with locally advanced or metastatic urothelial carcinoma: Retrospective analysis of Diagnosis Procedure Combination claims data in Japan.
Asakawa K, Waratani M, Massey O, Holbrook T, Kondo M, Saito A
Int J Urol. 2024; 31(7):730-738.
PMID: 38468564
PMC: 11524106.
DOI: 10.1111/iju.15450.
Differential expression of WNT5A long and short isoforms in non-muscle-invasive bladder urothelial carcinoma.
Strope A, Phillips C, Khadgi S, Jenkinson S, Coschigano K, Malgor R
Histol Histopathol. 2024; 39(6):715-727.
PMID: 38445662
DOI: 10.14670/HH-18-723.
Transporter Associated With Antigen Processing (TAP) 1 Gene Polymorphisms and Risks of Urothelial Cell Carcinoma Among the Japanese Population.
Aung K, Hlaing S, Damayanti P, Tabassum T, Tsukino H, Hinoura T
Cureus. 2024; 16(1):e52310.
PMID: 38357083
PMC: 10866181.
DOI: 10.7759/cureus.52310.
Prognostic model development and molecular subtypes identification in bladder urothelial cancer by oxidative stress signatures.
Dong Y, Wu X, Xu C, Hameed Y, Abdel-Maksoud M, N Almanaa T
Aging (Albany NY). 2024; 16(3):2591-2616.
PMID: 38305808
PMC: 10911378.
DOI: 10.18632/aging.205499.
Application of contrast-enhanced ultrasound in diagnosis and grading of bladder urothelial carcinoma.
Zhang H, Liang R, Lin X, Xue E, Ye Q, Zhu Y
BMC Med Imaging. 2024; 24(1):26.
PMID: 38273224
PMC: 10809509.
DOI: 10.1186/s12880-024-01199-3.
Summary of the Clinical Practice Guidelines for Upper Tract Urothelial Carcinoma 2023 by the Japanese Urological Association.
Mori K, Hatakeyama S, Enokida H, Miyake H, Kikuchi E, Nishiyama H
Int J Urol. 2023; 31(3):194-207.
PMID: 38113344
PMC: 11524111.
DOI: 10.1111/iju.15362.
The Relationship Between PD-1(rs2227981) and PD-L1(rs2890658) Polymorphisms and Urothelial Cell Carcinoma.
Hlaing S, Damayanti P, Aung K, Tsukino H, Hinoura T, Kuroda Y
Cureus. 2023; 15(11):e48120.
PMID: 38046711
PMC: 10693471.
DOI: 10.7759/cureus.48120.